Safety and Efficacy of Avacopan in Patients with Complement 3 Glomerulopathy
The primary end point for the study was not met; other clinical effects of avacopan to improve certain key kidney function parameters and slow disease progression were variable and require further evaluation.
Authors
- Jeffrey Petersen (ORCID: https://orcid.org/0009-0004-0222-5294)
- Andrew S. Bomback (ORCID: https://orcid.org/0000-0001-5449-1667)
- Priyanka Punit Kedia
- Richard Lafayette (ORCID: https://orcid.org/0000-0003-3906-7934)
- Leal Herlitz (ORCID: https://orcid.org/0000-0003-2665-8559)
- Huibin Yue
Institutions
- Cleveland Clinic (US)
- Amgen (United States) (US)
- Columbia University Irving Medical Center (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- Journal of the American Society of Nephrology
- Published
- 2024-10-11
- DOI
- https://doi.org/10.1681/asn.0000000526
- Citations
- 28
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 9.50